76P Immune checkpoint inhibitor (ICI) retreatment patterns and outcomes in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who received second-line or later (2L+) nivolumab (nivo): A French I-O optimise analysis

G. Justeau, M. Pérol,C. Audigier Valette, D. Debieuvre, X. Quantin, H. Lena, P. Macouillard, L. Bosquet, M.J. Schoemaker, M. Mella, B. Correia, C. Rault, M.J. Daumont, J. Penrod, C. Chouaid

Immuno-Oncology and Technology（2023）

引用 0|浏览1